Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Advances in prostate cancer treatment

Nature Reviews Drug Discovery volume 12, pages 823–824 (2013)Cite this article

Subjects

Current treatments

For stage I–III patients the standard treatment includes surveillance, prostatectomy and radiotherapy. For all stage IV and high-risk stage III patients, androgen ablation by surgical or chemical castration can bring about sustained remission. First-generation anti-androgens such as flutamide and bicalutamide assist in this setting. However, castration resistance, which is characterized by genomic mutations in the androgen receptor (AR)2, inevitably develops in the stage IV setting, at which point the prognosis is poor. The historic standard treatment for metastatic castration-resistant prostate cancer (CRPC), docetaxel, provides a median overall survival improvement of roughly 3 months.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Pipeline products by stage of development and mechanism of action.

References

  1. Siegel, R. et al. Cancer Statistics, 2012. CA Cancer J. Clin. 62, 10–29 (2012).

    Article  Google Scholar 

  2. Amaral, T. M. S. et al. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer http://dx.doi.org/10.1155/2012/327253 (2012).

  3. Cookson, M. S. et al. Castration-resistant prostate cancer: AUA Guideline. American Urological Association [online], (2013).

    Google Scholar 

Download references

Acknowledgements

GBI Research would like to thank G. Sonpavde M.D., at the University of Alabama, Birmingham, USA, for his scientific advice.

Author information

Authors and Affiliations

  1. Dominic Trewartha and Kimberley Carter are analysts at GBI Research, Bolton, BL1 2AH, UK.,

    Dominic Trewartha & Kimberley Carter

Authors
  1. Dominic Trewartha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberley Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominic Trewartha.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trewartha, D., Carter, K. Advances in prostate cancer treatment. Nat Rev Drug Discov 12, 823–824 (2013). https://doi.org/10.1038/nrd4068

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4068

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing